A Phase II Multi-Centre Study Evaluating the Efficacy of Dacomitinib for Patients With Epidermal Growth Factor Receptor (EGFR)-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expression or Other Novel Emerging Biomarkers
Latest Information Update: 07 Feb 2024
At a glance
- Drugs Dacomitinib (Primary)
- Indications Head and neck cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Biomarker; Therapeutic Use
- 01 Feb 2024 Planned End Date changed from 1 Jul 2026 to 1 Jun 2028.
- 16 Nov 2021 Status changed from not yet recruiting to recruiting.
- 08 Jul 2021 New trial record